Nektar Therapeutics

Nektar Therapeutics

Health CarePharmaceuticals & Biotechnology
  • Price (USD)35.71
  • Today's Change0.37 / 1.05%
  • Shares traded293.43k
  • 1 Year change-38.61%
  • Beta2.7296
Data delayed at least 15 minutes, as of Jun 20 2019 16:28 BST.
More ▼

Profile data is unavailable for this security.

About the company

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

  • Revenue in USD (TTM)1.18bn
  • Net income in USD658.64m
  • Incorporated1998
  • Employees618.00
  • Location
    Nektar Therapeutics455 Mission Bay Blvd SSAN FRANCISCO 94158-2158United StatesUSA
  • Phone+1 (415) 482-5300
  • Fax+1 (302) 655-5049
  • Websitehttp://www.nektar.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Syneos Health Inc4.45bn17.61m4.91bn24.00k316.961.7317.231.100.1490.160442.5227.360.6086--3.83185,496.900.24071.210.29421.560.690823.530.39551.65--2.870.49880.0064.3034.56152.44--25.25--
Novocure Ltd269.25m-54.99m5.34bn598.00--41.70--19.59-0.5918-0.59182.891.320.79933.677.35450,255.80-16.32-39.14-19.71-45.5269.6962.96-20.42-86.994.39-2.770.5416--40.1388.7334.11--13.10--
Moderna Inc122.05m-458.66m5.36bn760.00--3.50--41.51-1.39-1.390.374.40------160,597.40-------------364.61------0.0226---34.38---48.92------
Ascendis Pharma A/S17.89m-159.54m5.57bn216.00--7.06--312.81-3.76-3.760.423617.120.0283--840.3782,843.55-25.27-47.76-26.43-54.24-----891.58-940.49----0.0238--591.57-12.31-5.00--17.25--
Nektar Therapeutics1.18bn658.64m5.86bn618.009.483.568.694.923.523.526.749.380.88882.0740.461,915,092.0049.4616.4453.0518.3498.0492.9555.6525.9414.8314.960.1315--287.8151.62349.85--28.33--
Perrigo Company PLC4.69bn114.00m5.91bn10.60k51.621.0311.191.250.83650.836534.2041.920.41213.304.15442,377.301.00--1.17--38.12--2.43--1.143.600.3608---4.34---2.75------
Amarin Corporation plc (ADR)258.57m-116.78m5.91bn530.00--50.22--23.12-0.3807-0.38070.83930.42610.87961.314.36487,875.50-39.73-43.83-76.10-70.2776.4073.06-45.16-64.291.84-15.060.3453--26.5654.13-92.58--32.88--
Exelixis, Inc.855.59m649.99m6.05bn484.009.464.299.026.952.082.082.744.590.73863.197.171,767,756.0056.1112.2361.7116.2196.7096.5475.9722.507.48--0.000.0088.7093.67347.44--72.64--
PRA Health Sciences Inc2.89bn154.91m6.30bn16.40k41.205.6823.522.182.332.3943.4916.890.8607--4.86176,348.004.622.936.473.9228.5429.055.373.74--6.740.49260.0027.1123.7156.71--23.17--
Array Biopharma Inc239.57m-126.12m6.45bn298.00--21.73--27.39-0.589-0.5891.121.360.4503--6.32803,936.30-23.71-39.95-28.27-54.5892.4062.57-52.64-77.795.65-24.490.308--15.1920.09-26.13---12.04--
bluebird bio Inc51.09m-604.95m6.47bn827.00--3.66--126.94-11.36-11.360.958932.180.0255----66,875.66-30.21-25.40-32.26-27.00-----1,184.01-1,088.20----0.00--54.0622.02-25.81--45.09--
Charles River Laboratories Intl. Inc2.38bn221.85m6.48bn14.70k28.664.5115.812.654.514.6648.3728.680.686212.115.08161,679.906.477.017.548.3936.6237.809.4310.201.395.850.5250.0021.9914.228.6016.0829.03--
Data as of Jun 20 2019. Currency figures normalised to Nektar Therapeutics's reporting currency: US Dollar USD

Institutional shareholders

64.03%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co.as of 31 Mar 201920.13m11.55%
PRIMECAP Management Co.as of 31 Mar 201919.36m11.10%
The Vanguard Group, Inc.as of 31 Mar 201917.92m10.28%
OppenheimerFunds, Inc.as of 31 Mar 201917.30m9.93%
Wellington Management Co. LLPas of 31 Mar 201912.96m7.44%
BlackRock Fund Advisorsas of 31 Mar 20199.54m5.47%
SSgA Funds Management, Inc.as of 31 Mar 20197.10m4.07%
Henderson Global Investors Ltd.as of 31 Mar 20192.46m1.41%
Bellevue Asset Management AGas of 31 Mar 20192.45m1.41%
Geode Capital Management LLCas of 31 Mar 20192.40m1.38%
More ▼
Data from 31 Mar 2019 - 31 Mar 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.